Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response - Dela Cruz Chuh, Josefa; Go, MaryAnn; Chen, Yvonne; Guo, Jun; Rafidi, Hanine; Mandikian, Danielle; Sun, Yonglian; Lin, Zhonghua; Schneider, Kellen; Zhang, Pamela; Vij, Rajesh; Sharpnack, Danielle; et al. (mAbs, 2021)
Keywords: ADC resistance; Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - pharmacology; antibody discovery; Antibody-drug conjugate; Antigens, Surface - immunology; Antineoplastic Agents - immunology; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Antineoplastic Agents, Immunological - pharmacokinetics; Antineoplastic Agents, Immunological - pharmacology; Cell Line, Tumor; Cell Survival - drug effects; Cell Survival - immunology; Female; GPI-Linked Proteins - immunology; HEK293 Cells; Humans; Immunoconjugates - immunology; Immunoconjugates - pharmacokinetics; Immunoconjugates - pharmacology; Ly6E; Mice; Mice, SCID; Oligopeptides - immunology; Rats; Rats, Sprague-Dawley; Tumor Burden - drug effects; Tumor Burden - immunology; virus-like particles; Xenograft Model Antitumor Assays - methods; ADC resistance; Ly6E; virus-like particles; antibody discovery; Antibody-drug conjugate